Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Cardiovascular comorbidity and its impact on patients with COVID-19

  1. Wei-jie Guan1,3,
  2. Wen-hua Liang2,3,
  3. Jian-xing He2⇑ and
  4. Nan-shan Zhong1
  1. 1State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
  2. 2Dept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  3. 3Wei-jie Guan and Wen-hua Liang are joint first authors
  1. Jian-xing He, Dept of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China. E-mail: drjianxing.he{at}gmail.com

Abstract

Comorbid hypertension correlates with poorer outcomes in patients with COVID-19 https://bit.ly/2zoT9f0

From the authors:

We truly appreciate the comments from C.E. Leiva Sisnieguez and colleagues, who have performed a further analysis on the potential association between cardiovascular comorbidities and the clinical outcomes of coronavirus disease 2019 (COVID-19), particularly the mortality). We also applaud the suggestion to thoroughly adjust for potential confounding factors when interpreting the association between specific categories of cardiovascular comorbidities (e.g. hypertension) and the clinical outcomes of COVID-19. To this end, we have attempted to incorporate the cardiovascular diseases (including coronary heart disease) into the multivariate regression model [1]. Findings of the model indicated a prominent collinearity between hypertension and coronary heart disease, and we have therefore elected to retain hypertension in the regression model for further analyses.

Like other comorbidities, such as COPD, information about cardiovascular comorbidities was derived from patient self-report, which does not preclude under-reporting. Therefore, the percentage of patients with cardiovascular diseases might have been underestimated given the urgency of data collection (history taking) within the wards during the outbreak. Our findings could also have been attributed to the relatively low proportion of patients with coexisting hypertension and coronary heart disease in our study. Nonetheless, the overall proportion of patients with comorbidities in our study [1] was in keeping with previous publications [2–6]. Our findings were likely to be generalisable to other populations worldwide.

The cause of the association between cardiovascular diseases and the poor clinical outcome of COVID-19 may be multifaceted, including, but not limited to, age and cardiac dysfunction caused by viral infections. As ours was a cross-sectional case study, causality could not be inferred from the study design. Dynamic monitoring of cardiovascular symptoms, cardiac function and laboratory markers might help unravel the underlying pathways linking cardiovascular diseases to the poor clinical outcomes of COVID-19.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01227-2020.Shareable

Footnotes

  • Author contributions: Wei-jie Guan and Wen-hua Liang drafted the manuscript; all authors provided critical review of the manuscript and approved the final draft for publication.

  • Conflict of interest: Wei-jie Guan has nothing to disclose.

  • Conflict of interest: Wen-hua Liang has nothing to disclose.

  • Conflict of interest: Jian-xing He has nothing to disclose.

  • Conflict of interest: Nan-shan Zhong reports grants from National Health Commission and Dept of Science and Technology of Guangdong Province, during the conduct of the study.

  • Support statement: Supported by National Health Commission, Dept of Science and Technology of Guangdong Province. The funder had no role in the conduct of the study. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received April 17, 2020.
  • Accepted April 17, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

    1. Guan W-j,
    2. Liang W-h,
    3. Zhao Y, et al.
    Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55: 2000547. doi:10.1183/13993003.00547-2020
    1. Placzek HED,
    2. Madoff LC
    . Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts. Am J Public Health 2014; 104: e118–e125. doi:10.2105/AJPH.2014.302197
    1. Booth CM,
    2. Matukas LM,
    3. Tomlinson GA, et al.
    Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289: 2801–2809. doi:10.1001/jama.289.21.JOC30885
    1. Alqahtani FY,
    2. Aleanizy FS,
    3. Ali Hadi Mohammed R, et al.
    Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect 2018; 5: 1–5.
    1. Badawi A,
    2. Ryoo SG
    . Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV). Int J Infect Dis 2016; 49: 129–133. doi:10.1016/j.ijid.2016.06.015
    1. Alanazi KH,
    2. Abedi GR,
    3. Midgley CM, et al.
    Diabetes mellitus, hypertension, and death among 32 patients with MERS-CoV infection, Saudi Arabia. Emerging Infect Dis 2020; 26: 166–168. doi:10.3201/eid2601.190952

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society